NZ630721A - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use - Google Patents

Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Info

Publication number
NZ630721A
NZ630721A NZ630721A NZ63072113A NZ630721A NZ 630721 A NZ630721 A NZ 630721A NZ 630721 A NZ630721 A NZ 630721A NZ 63072113 A NZ63072113 A NZ 63072113A NZ 630721 A NZ630721 A NZ 630721A
Authority
NZ
New Zealand
Prior art keywords
pyrazolo
pyrimidine
compositions
methods
based compounds
Prior art date
Application number
NZ630721A
Other languages
English (en)
Inventor
Kenneth Gordon Carson
Giovanni Cianchetta
Yingzhi Bi
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NZ630721A publication Critical patent/NZ630721A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ630721A 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use NZ630721A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
NZ630721A true NZ630721A (en) 2016-12-23

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630721A NZ630721A (en) 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Country Status (25)

Country Link
US (3) US8946415B2 (enEXAMPLES)
EP (1) EP2834243B1 (enEXAMPLES)
JP (1) JP6418950B2 (enEXAMPLES)
KR (1) KR101965025B1 (enEXAMPLES)
CN (1) CN104302649B (enEXAMPLES)
AR (1) AR090292A1 (enEXAMPLES)
AU (1) AU2013230128B2 (enEXAMPLES)
BR (1) BR112014022000A8 (enEXAMPLES)
CA (1) CA2866143C (enEXAMPLES)
DK (1) DK2834243T3 (enEXAMPLES)
ES (1) ES2676224T3 (enEXAMPLES)
HU (1) HUE038786T2 (enEXAMPLES)
IL (1) IL234486A (enEXAMPLES)
IN (1) IN2014DN07384A (enEXAMPLES)
MX (2) MX381849B (enEXAMPLES)
NZ (1) NZ630721A (enEXAMPLES)
PL (1) PL2834243T3 (enEXAMPLES)
PT (1) PT2834243T (enEXAMPLES)
RU (1) RU2014140735A (enEXAMPLES)
SG (1) SG11201405561RA (enEXAMPLES)
TR (1) TR201808280T4 (enEXAMPLES)
TW (1) TW201341386A (enEXAMPLES)
UY (1) UY34668A (enEXAMPLES)
WO (1) WO2013134228A1 (enEXAMPLES)
ZA (1) ZA201406149B (enEXAMPLES)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022000A8 (pt) 2012-03-09 2021-06-15 Lexicon Pharmaceuticals Inc compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
NZ630719A (en) 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AP2016009383A0 (en) 2014-01-24 2016-08-31 Tp Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
EP3099673B1 (en) * 2014-01-31 2018-09-26 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
HRP20240937T1 (hr) * 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
WO2017004342A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
ES2979111T3 (es) 2015-07-06 2024-09-24 Turning Point Therapeutics Inc Polimorfo de macrociclo de diarilo
MX383823B (es) 2015-07-21 2025-03-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismo.
CN108349979B (zh) * 2015-11-02 2021-04-09 詹森药业有限公司 [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
BR112019008404A2 (pt) * 2016-11-02 2019-09-17 Janssen Pharmaceutica Nv derivados de [1,2,4]triazolo[1,5-a]pirimidina como inibidores da pde2
CN109890824B (zh) 2016-11-02 2022-05-24 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
RS65884B1 (sr) 2017-07-28 2024-09-30 Turning Point Therapeutics Inc Makrociklična jedinjenja i primene istih
JP7321183B2 (ja) * 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド がんを治療するためのtrkキナーゼ阻害物質としての、5-(2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-3-(1h-ピラゾール-1-イル)ピラゾロ[1,5-a]ピリミジン誘導体及び関連する化合物
CN111511746B (zh) 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
EP3730492A4 (en) * 2017-12-22 2021-08-11 Shenzhen TargetRx, Inc. COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
JP7162915B2 (ja) 2018-01-23 2022-10-31 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ[1,5-a]ピリミジン系大環状化合物
JP2022503932A (ja) * 2018-09-27 2022-01-12 フォチョン・ファーマシューティカルズ・リミテッド Retキナーゼ阻害剤としての置換イミダゾ[1,2-a]ピリジン及び[1,2,4]トリアゾロ[1,5-a]ピリジン化合物
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2021216441A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. Aak1 inhibitors for use in treating viral infections
WO2021216454A1 (en) * 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
WO2025054448A1 (en) * 2023-09-08 2025-03-13 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
SI2350071T1 (sl) * 2008-10-22 2014-05-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2011087999A1 (en) 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
US9416132B2 (en) * 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
BR112014022000A8 (pt) 2012-03-09 2021-06-15 Lexicon Pharmaceuticals Inc compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
EP2822555B1 (en) * 2012-03-09 2017-11-08 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
NZ630719A (en) 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
BR112014022000A2 (pt) 2017-06-20
CA2866143A1 (en) 2013-09-12
EP2834243B1 (en) 2018-04-25
AR090292A1 (es) 2014-11-05
CN104302649A (zh) 2015-01-21
ES2676224T3 (es) 2018-07-17
AU2013230128B2 (en) 2017-08-17
DK2834243T3 (en) 2018-07-23
UY34668A (es) 2013-10-31
JP2015509535A (ja) 2015-03-30
JP6418950B2 (ja) 2018-11-07
US20150183792A1 (en) 2015-07-02
BR112014022000A8 (pt) 2021-06-15
KR101965025B1 (ko) 2019-04-02
US8946415B2 (en) 2015-02-03
PL2834243T3 (pl) 2018-09-28
US9403832B2 (en) 2016-08-02
WO2013134228A1 (en) 2013-09-12
EP2834243A1 (en) 2015-02-11
SG11201405561RA (en) 2014-10-30
ZA201406149B (en) 2016-06-29
IN2014DN07384A (enEXAMPLES) 2015-04-24
MX381849B (es) 2025-03-13
TR201808280T4 (tr) 2018-07-23
AU2013230128A1 (en) 2014-09-25
HK1201257A1 (en) 2015-08-28
RU2014140735A (ru) 2016-04-27
PT2834243T (pt) 2018-08-01
TW201341386A (zh) 2013-10-16
US20170129896A1 (en) 2017-05-11
CN104302649B (zh) 2017-06-23
HUE038786T2 (hu) 2018-11-28
CA2866143C (en) 2020-08-04
MX345830B (es) 2017-02-17
US20130253194A1 (en) 2013-09-26
MX2014010589A (es) 2014-09-18
KR20140138864A (ko) 2014-12-04
IL234486A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
NZ600430A (en) Spiro-oxindole mdm2 antagonists
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NZ609957A (en) Heterocyclic compounds and uses thereof
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012030944A3 (en) Quinoline and isoquinoline derivatives for use as jak modulators
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
NZ702513A (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY CPA GLOBAL

Effective date: 20200123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY CPA GLOBAL

Effective date: 20210121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY CPA GLOBAL

Effective date: 20220121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250116